Dr Agarwals Eye Hospital

Healthcare Services

DRAGARWQ NSE

NSE: DRAGARWQ BSE: 526783 Hospitals

₹5,423.00 +154.00 (+2.92%)

P/E: 34.38

View as Markdown

MCP

Close 4 Nov 2026 ₹5,423.00 +199.05 +3.81% 1Y

Start ₹5,223.95

Key Fundamentals

MicrocapHealthcare ServicesHealthcare

Price-based figures as of 04 Nov 2026, 15:29 IST · EPS basis: Standalone · TTM

ROCE: 17.20%
Debt to Equity: 0.94
EPS (TTM): ₹157.72
Book Value: ₹716.56

Market Cap: —
P/E (TTM): 34.38
P/B: 7.57
ROE: 24.20%
Dividend Yield: 0.13%
EBITDA: ₹151 Cr
52W High: ₹6,392.00
52W Low: ₹4,412.05
Day Range: ₹5,230.00 – ₹5,439.00
Volume: 1,087

Peer Comparison

Healthcare › Healthcare Services › Hospitals › Hospital

Dr Agarwals Eye Hospital peer comparison

Apollo Hospitals	₹8,599.50	59.18	₹1,22,850 Cr	13.04	0.24%	21.20%	17.40%	₹26,430 Cr	₹2,171 Cr
Max Healthcare Institute	₹927.15	61.89	₹89,301 Cr	7.96	0.22%	14.70%	14.70%	₹8,712 Cr	₹1,457 Cr
Manipal Health Enterprises	₹667.20	88.96	₹86,479 Cr	5.34	0.00%	6.64%	8.30%	₹11,400 Cr	₹906 Cr
Aster DM Healthcare	₹719.55	117.00	₹59,927 Cr	14.91	0.44%	11.30%	11.60%	₹4,876 Cr	₹363 Cr
Fortis Healthcare	₹790.65	56.96	₹59,706 Cr	6.03	0.13%	11.20%	13.40%	₹9,506 Cr	₹1,070 Cr
Narayana Hrudayalaya	₹1,931.50	48.36	₹39,090 Cr	7.89	0.24%	20.50%	15.50%	₹9,072 Cr	₹816 Cr
Global Health	₹1,402.00	67.76	₹37,618 Cr	9.52	0.04%	15.20%	17.40%	₹4,683 Cr	₹552 Cr
Dr Agarwals Eye Hospital (this company)	₹5,423.00	34.38	₹2,549 Cr	7.57	0.13%	24.20%	17.20%	₹497 Cr	₹75 Cr
Median 8 companies	₹1,164.58	60.54	₹59,817 Cr	7.93	0.18%	14.95%	15.10%	₹8,892 Cr	₹861 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of 4 Nov 2026. How it works →

Overall score

56 Good

Data confidence 100/100

Category scores

Quality: 81; Strong; Returns, margins, earnings quality 22% weight
Valuation: 42; Weak; Cheap vs sector & own history 24% weight
Growth: 70; Strong; Sales & profit trajectory 9% weight
Financial Health: 35; Poor; Solvency, leverage, coverage 9% weight
Momentum: 43; Weak; Trend strength, vol-adjusted 12% weight
Ownership: 63; Good; FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

Company has delivered good profit growth of 118% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 28.2%

Weaknesses

Stock is trading at 7.28 times its book value
Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
Group	Signal	Bearish	Neutral	Bullish
Overall	Strong Bullish	3	4	12
Oscillators	Bearish	3	4	2
Moving Averages	Strong Bullish	0	0	10

Oscillators

Bearish

Neutral

Bullish

Overall

Strong Bullish

Bearish

Neutral

Bullish

Moving Averages

Strong Bullish

Bearish

Neutral

Bullish

Key readings

RSI (14): 60.36; Neutral
MACD (12,26,9): 38.36; Bullish
SMA (50): 5,225.19; Bullish
SMA (200): 5,007.32; Bullish

As of 4 Nov 2026

Analyst Rating

Based on 1 analysts

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

As of 4 Nov 2026

BUY

100%

HOLD

SELL

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y	+13.14%
5Y	+27.46%
3Y	+20.68%
1Y	+18.64%
TTM	+20.05%

Net profit

Net profit growth by window
10Y	Zero base
5Y	Turned to profit
3Y	+23.68%
1Y	+27.27%
TTM	+31.58%

Operating cash flow

Operating cash flow growth by window
10Y	+23.91%
5Y	+33.65%
3Y	+27.47%
1Y	+54.26%
TTM	—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y	+18.07 pp
5Y	+9.07 pp
3Y	+2.85 pp
1Y	+0.98 pp
TTM	+0.19 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017	₹149 Cr
Mar 2018	₹153 Cr
Mar 2019	₹170 Cr
Mar 2020	₹176 Cr
Mar 2021	₹140 Cr
Mar 2022	₹201 Cr
Mar 2023	₹268 Cr
Mar 2024	₹319 Cr
Mar 2025	₹397 Cr
Mar 2026	₹471 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017	₹7.00 Cr
Mar 2018	₹7.00 Cr
Mar 2019	₹12.00 Cr
Mar 2020	₹14.00 Cr
Mar 2021	−₹1.00 Cr
Mar 2022	₹24.00 Cr
Mar 2023	₹37.00 Cr
Mar 2024	₹46.00 Cr
Mar 2025	₹55.00 Cr
Mar 2026	₹70.00 Cr

Analyst Forecasts

Forecast For

FY27 consensus · EBITDA

₹706 Cr

Reported High Mean Low

Analyst consensus here uses a different definition from reported ebitda (they differ 3.7× on periods where both exist), so the forecast is shown on its own rather than joined to the reported line.

Quarterly Results

₹ Cr

526783 quarterly results, ₹ crore
Particulars	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	79	84	76	81	100	102	95	100	117	118	116	120	143
Expenses	56	61	55	56	69	72	69	68	80	78	82	86	100
Operating Profit	23	23	21	24	31	30	26	32	37	40	34	34	43
OPM %	29%	28%	27%	30%	31%	29%	27%	32%	32%	34%	30%	28%	30%
Other Income	0	1	1	2	0	2	2	0	1	1	3	2	2
Interest	2	2	2	2	3	4	4	3	4	4	2	2	3
Depreciation	6	6	7	8	10	9	10	10	11	11	12	12	11
PBT	16	17	13	17	19	19	14	19	23	26	23	21	31
Tax %	26%	24%	26%	26%	25%	26%	26%	14%	26%	25%	26%	24%	24%
Net Profit	12	13	9	13	14	14	10	16	17	19	17	16	23
EPS (₹)	24.55	26.79	20.09	27.21	30.02	30.11	22.13	34.02	36.72	39.98	35.76	33.6	48.38

Profit & Loss

₹ Cr

526783 profit and loss, annual, ₹ crore
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	118	137	149	153	170	176	140	201	268	319	397	471	497
Expenses	103	119	126	129	140	129	109	143	192	227	277	324	345
Operating Profit	15	18	23	24	30	47	31	59	76	92	120	147	151
OPM %	13%	13%	15%	16%	18%	27%	22%	29%	28%	29%	30%	31%	30%
Other Income	0	−5	1	2	2	3	1	1	2	5	5	6	7
Interest	4	5	4	3	4	9	7	7	8	8	15	14	10
Depreciation	6	9	9	10	11	21	19	20	20	27	39	46	47
PBT	5	0	11	13	17	20	6	32	49	62	71	94	101
Tax %	−6%	−104%	33%	49%	32%	31%	125%	25%	25%	26%	23%	25%	—
Net Profit	6	0	7	7	12	14	−1	24	37	46	55	70	76
EPS (₹)	12.13	0.09	15.62	14.43	25.36	29.11	−3.06	51.28	78.55	98.64	116	145	158
Div. Payout %	10%	940%	10%	8%	6%	0%	0%	6%	4%	3%	5%	5%	—

Balance Sheet

₹ Cr

526783 balance sheet, annual, ₹ crore
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	5	5	5	5	5	5	5	5	5	5	5	5
Reserves	19	19	25	30	41	51	50	73	109	152	205	341
Borrowings	27	31	23	18	24	60	68	193	232	268	333	326
Other Liabilities	18	24	20	28	31	24	33	42	44	71	71	94
Total Liabilities	69	79	72	81	100	141	155	314	390	496	613	766
Fixed Assets	26	34	33	36	55	94	96	214	260	316	393	403
CWIP	0	1	1	3	0	0	0	26	62	97	128	197
Investments	0	0	0	0	0	0	0	0	0	0	13	89
Other Assets	43	44	38	42	45	47	60	73	67	83	80	78
Total Assets	69	79	72	81	100	141	155	314	390	496	613	766

Cash Flow

₹ Cr

526783 cash flow, annual, ₹ crore
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating	14	17	20	19	25	39	34	57	70	90	94	145
Investing	−10	−17	−8	−11	−25	−17	−11	−46	−71	−70	−133	−174
Financing	−5	0	−12	−8	2	−20	−8	−4	0	−14	17	25
Net Cash Flow	−1	0	0	0	2	2	15	7	−1	6	−23	−4
Free Cash Flow	3	1	12	7	0	22	23	10	−1	19	−9	47
CFO/OP	106	113	103	98	111	96	120	112	107	112	95	105

Ratios

526783 financial ratios, annual
Particulars	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	19	24	16	17	19	14	23	16	14	15	13	14
Inventory Days	238	200	123	148	124	132	117	91	73	106	55	51
Days Payable	360	371	277	353	292	224	401	410	327	345	101	97
Cash Conversion Cycle	−103	−146	−138	−189	−149	−78	−260	−303	−240	−224	−34	−31
Working Capital Days	−31	−39	−25	−39	−22	−34	−70	−58	−50	−63	−51	−55
ROCE %	19%	18%	29%	32%	34%	30%	11%	20%	19%	18%	18%	17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

62 extracted metrics across FY15–FY27.

Shareholding Pattern

As of Sep 2026

Promoters 72.67%
Public 17.58%
Others 4.99%
DIIs 2.54%
FIIs 2.22%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Concall · Aug 2025
PPT

Frequently Asked Questions about Dr Agarwals Eye Hospital

What does Dr Agarwals Eye Hospital Ltd do?

Dr Agarwal's Eye Hospital Ltd is a leading chain of eye hospitals with predominant presence in Tamil Nadu.

Where is Dr Agarwals Eye Hospital Ltd (DRAGARWQ) listed?

Dr Agarwals Eye Hospital Ltd trades as DRAGARWQ on the NSE and under code 526783 on the BSE.

Which sector does Dr Agarwals Eye Hospital Ltd belong to?

Dr Agarwals Eye Hospital Ltd is classified under the Healthcare Services sector, in the Hospitals industry.

What is the PE ratio of Dr Agarwals Eye Hospital Ltd?

Dr Agarwals Eye Hospital Ltd trades at a PE ratio of 34.38 as of 4 Nov 2026, on earnings per share of ₹157.72, against a book value of ₹716.56 per share.

What is the 52-week high and low of Dr Agarwals Eye Hospital Ltd?

Over the last 52 weeks Dr Agarwals Eye Hospital Ltd has traded between ₹4,412.05 and ₹6,392 as of 4 Nov 2026.

Does Dr Agarwals Eye Hospital Ltd pay dividends?

Dr Agarwals Eye Hospital Ltd has a dividend yield of 0.13%.

What is the Return on Equity (ROE) of Dr Agarwals Eye Hospital Ltd?

Dr Agarwals Eye Hospital Ltd reported a return on equity of 24.20%. Its debt-to-equity ratio is 0.94.

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/526783.md for Dr Agarwals Eye Hospital Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List FII and DII flows, month by month How Tapetide Scores changed, month by month Stocks mutual funds are buying, month by month

Dr Agarwals Eye Hospital

Key Fundamentals

Peer Comparison

Overall score

Category scores

Key Insights

Strengths

Weaknesses

Technical Indicators

Oscillators

Overall

Moving Averages

Key readings

Analyst Rating

Growth Rate

Revenue

Net profit

Operating cash flow

Operating margin· change in pp

Revenue by year

Net profit by year

Analyst Forecasts

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Insights

Shareholding Pattern

Documents

Frequently Asked Questions about Dr Agarwals Eye Hospital

Company Information

For AI agents and developers

Explore More